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 FAM171B is a relatively uncharacterized protein that contains fourteen 
consecutive glutamine residues within its primary amino acid sequence; thus it is a 
polyglutamine (polyQ) protein. PolyQ proteins are interesting because mutations within 
the polyQ tract have been linked to a number of severe neurodegenerative diseases 
including Huntingtons Disease (HD). To date, there are minimal published data regarding 
FAM171B and its molecular function, such that both expression levels and intracellular 
localization have yet to be definitively determined. Using immunohistochemical and in 
situ hybridization analyses, our lab has recently found that FAM171B is expressed 
throughout the mouse brain. This current study attempts to build off this information to 
identify the intracellular localization of FAM171B in several different nervous system 
cell types including: a human glioblastoma cell line (U138), a human neuroblastoma cell 
line (SH-SY5Y), and mouse brain primary neurons. Using immunofluorescence, 
FAM171B-GFP fusion proteins, and live cell imaging (coupled with confocal 
microscopy) our data indicate that FAM171B has a predominantly vesicular/punctate 
staining within the cytoplasm of cells. Furthermore, colocalization studies using organelle 
specific markers shows that FAM171B localizes to both endosomes and cellular regions 
near the plasma membrane. Taken together, our data suggests that FAM171B may play a 
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Figure    Description 
 
1 FAM171B displays a punctate cytoplasmic staining in 
primary neurons, SH-SY5Y cells and U138 cells. 
(Immunofluorescence, Novus 93847 rabbit polyclonal Ab). 
2 FAM171B displays a punctate cytoplasmic staining in 
primary neurons, SH-SY5Y cells and U138 cells. 
(Immunofluorescence, Novus 93846 rabbit polyclonal Ab). 
3 Orthogonal view of the merged image of U138 
(Immunofluorescence, Novus 93846 rabbit polyclonal Ab) 
indicates FAM171B predominantly localizes to the 
cytoplasm of the cell. 
4 Orthogonal view of the merged image of Sh-SY5Y 
(Immunofluorescence, Novus 93846 rabbit polyclonal Ab) 
indicates FAM171B predominantly localizes to the 
cytoplasm of the cell. 
5 Orthogonal view of the merged image of Primary neuron 
(Immunofluorescence, Novus 93846 rabbit polyclonal Ab) 
indicates FAM171B predominantly localizes to the 




6 FAM171B-GFP displays a punctate signaling pattern in 
U138 cells (fixed). 
7 Orthogonal view of transfected U138 cell with FAM171B-
GFP (merged image) indicates FAM171B localizes 
predominantly to the cytoplasm of the cell. 
8 FAM171B-FLAG localizes to the cytoplasm of U138 cells 
(fixed). 
9 Orthogonal view of the merged image of U138 cell 
transfected with FAM171B-FLAG shows FAM171B 
predominantly localizing to the cytoplasm of the cell. 
10 FAM171B-GFP exhibits similar expression pattern at 
different plasmid concentrations in U138 cells. 
11 FAM171B is expressed in the cytoplasm of neurons. 
12 FAM171B does not colocalize to mitochondria in primary 
neurons. 
13 Orthogonal view of the merged image of primary neuron, 
subjected to co-immunofluorescence with antibody against 
FAM171B (Novus 93846) and mitochondria.  
14 FAM171B localizes to pseudopod protrusions near the 
plasma membrane in cells. 








 Homopeptide repeats are consecutive stretches of the same amino acid within a 
protein’s primary sequence. They are a common protein motif, and it has been suggested 
that at least certain homopeptide amino acid repeats may serve as protein-protein 
interaction domains (1).  Polyglutamine (polyQ) tracts, a specific type of homopeptide 
repeat consisting of multiple consecutive glutamine (Q) amino acid residues are present 
in more than 60 human proteins (2). Indeed, some lower organisms (such as the amoeba 
Dictyostellium discoideum) possess several hundred (3). PolyQ tracts in proteins are often 
polymorphic in repeat copy number. However the function of polyQ tracts within 
proteins, and the putative consequence of this normal Q repeat copy number variation has 
yet to be definitively determined (2,3). 
 Interestingly, expansion mutation of polyQ (CAG repeats) tracts well beyond 
their normal polymorphic range in certain proteins leads to severe inherited 
neurodegenerative diseases, known collectively as polyglutamine diseases. In 1991, 
Fischbeck and coworkers first reported the disease associated expansion of CAG repeat 
in exon 1 of the androgen receptor gene in patients of spinal and bulbar muscular atrophy 
(SBMA) (4). Since then, similar genetic mutations of the CAG repeat expansion in the 
coding regions of genes other than androgen receptor gene have been found in other 
inherited neurodegenerative disorders. To date, a total of nine polyQ disorders have been 




(HD); dentatorubral pallidoluysian atrophy (DRPLA); and spinal and bulbar muscular 
atrophy.  In each disease, the specific translated polyQ protein leads to dysfunction and 
degeneration of select neuronal subpopulations (Table1) 
Table 1. Summary of the nine inherited Polyglutamine disorders 
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 PolyQ diseases are relatively rare, averaging 1–10 cases per 100,000 people (5).  
Of polyQ disorders, HD and SCA3 have the highest prevalence worldwide (6). 
 While the genes associated with the different polyQ diseases are structurally and 
functionally distinct, there are commonalities across all of these diseases. With the 
exception of SBMA, which is X-linked (and displays sex-limited inheritance), all other 
polyQ diseases are inherited in autosomal dominant pattern (7). All are 
neurodegenerative disorders, with disease onset typical in midlife and slowly progressive 
phenotypes. Certain pathologic molecular processes have been implicated in almost all of 
the polyQ diseases, including protein aggregation, proteolytic cleavage, transcription 
dysregulation, autophagy impairment, and mitochondrial dysfunction (7).  
 Curiously, polyQ containing proteins are ubiquitously expressed throughout the 
body, while the pathology is primarily restricted to neuronal tissue, displaying cell-type 
specificity or selective vulnerability (8). The mechanisms that are responsible for this 
specificity are largely unknown (7). However, the amino acid context of the polyQ 
proteins and their interacting protein partners may help determine the selective neuronal 
cell loss seen in distinct brain regions affected in polyQ diseases (9). 
 Importantly, the length of the polyQ repeat is critical to pathogenesis and for each 
disease (Table 1). There seems to be a critical threshold of polyQ expansion that must be 
exceeded in order to cause disease (10,11). For example, Huntington has a polyQ tract at 
its amino-terminus with a normal repeat length ranging from 5-35 repeats. In contrast, the 
polyQ tract in HD patients is abnormally expanded to greater than 40 consecutive 




(11,12). Interestingly, the longer the polyQ repeat tract length- the more severe HD 
manifests (13). Also, expanded polyQ regions are inherently unstable and tend to expand 
further, resulting in an earlier age of onset and a more severe disease phenotype in 
successive familial generations (13).  Indeed, this “genetic anticipation” is a prominent 
feature of all polyQ diseases (13).  
 The best studied pathology, HD, usually involves the loss of neurons in the 
striatum and layers III and V of the cortex, which affects muscle coordination and leads 
to cognitive impairment and psychiatric problems (5). The IT15 gene that encodes the 
Huntingtin (Htt) protein is located on the short arm of chromosome four. Huntingtin is 
widely expressed in neuronal and non‐neuronal tissues, but its level in the striatum is 
higher than in other organs (14). The functions of normal htt are not yet completely 
known, but it is suggested that non‐mutated htt is involved in cellular trafficking and may 
function as a scaffold protein (15). 
 Spinocerebellar ataxia types 1–3, 6, and 7 are the most frequent among autosomal 
dominantly inherited cerebellar ataxia (ADCA) syndromes and account for 50-60% of all 
families affected by ADCA worldwide (16). Major symptoms of ataxia, such as 
imbalance and incoordination, are indicative of impairment of cerebellar functions, which 
results mainly from a massive loss of Purkinje cells. Ataxias are often accompanied by 
dysarthria, rigidity, and dystonia, as well as by oculomotor disorders (17). 
 Dentatorubral-pallidoluysian atrophy (DPRLA) is caused by a mutation in the 




1). DRPLA patients show a wide variety of progressive neurological deficits like ataxia, 
myoclonus, epilepsy, and dementia (5). 
 Spinal and bulbar muscular atrophy (SBMA), or Kennedy's disease, is 
characterized by slowly progressing muscle weakness and atrophy of the bulbar, facial, 
and limb muscles (18). Pathologically, SBMA is associated with loss of motor neurons in 
the spinal cord and brainstem. SBMA is caused by an abnormal expansion of CAG 
repeats in exon 1 of the androgen receptor (AR) gene on chromosome Xq11-12 (19). 
 Determination of the structure of polyQ regions has been difficult, as they appear 
to be unstable (1). However, abnormally expanded polyQ stretches likely undergo a 
conformational transition to a ß-sheet rich structure, which causes these proteins to 
assemble into amyloid fibril insoluble aggregates (12).  Indeed, neuronal inclusion bodies 
composed of aggregated expanded polyQ proteins have been linked to cell death and 
neurodegeneration leading to behavioral and physical impairments (12).  Several studies 
have linked these polyQ aggregates to cellular toxicity. For example, overexpression of 
chaperone proteins slow aggregation and decreased toxicity in both cellular and animal 
models (20). Both loss-of-normal-function and toxic-gain of function mechanisms have 
been posited to explain toxicity, but the case for latter is stronger (20). Unfortunately, to 
date, there is neither a cure nor prevention for these devastating diseases (9,13) 
Our lab is interested in characterizing FAM171B, a novel polyQ protein that has 
yet to be linked to a neurodegenerative disease. Bioinformatic analysis suggests that, 
similar to huntingtin, FAM171B has a stretch of consecutive glutamine amino acids near 




regarding the molecular function of this novel protein. For example, it is unknown 
whether the polyQ tract is polymorphic in humans. Similarly, FAM171B expression 
levels and subcellular localization have yet to be definitively determined.  
Recent studies in our lab using in situ hybridization and immunohistochemistry 
strongly suggest that FAM171B is expressed throughout the brain- elevating its status as 
a candidate gene for an as yet molecularly uncharacterized neurodegenerative disease 
(unpublished data). Furthermore, examination of regions within the brain, indicate that 
FAM171B is expressed more prominently in certain brain areas compared to others. For 
example, the hippocampus shows very high FAM171B expression at both the mRNA and 
protein level. The hippocampus is a complex brain structure embedded deep into 
temporal lobe and it has a major role in learning and memory. The hippocampus is also 
important in spatial navigation, emotional behavior and regulation of hypothalamic 
functions (21). Many polyQ diseases such as HD, SBMA, DRPLA result in dementia and 
impaired memory (22) which could be due to failure in hippocampal activity. High levels 
of FAM171B are also found in the cerebellum. The cerebellum plays an important role in 
the motor system coordination. Severe abnormalities of movement are produced by 
pathologies of the cerebellum (23). Other non-motor functions of cerebellum includes 
attention, executive control, language, working memory, learning, pain, emotion, and 
addiction (24). In many polyQ diseases atrophic changes in the cerebellum is a prominent 
feature (13). 
 Further bioinformatic analysis suggests that FAM171B has a number of other 




sites, and transmembrane regions (unpublished data). However, whether any of these 
putative domains actually function as predicted remains to be determined. Thus, these in 
silico analyses provide hints into molecular structure and function that need to be 
empirically verified via benchtop experiments.  
      An AT- hook is a small DNA binding motif and it was first described in high 
mobility group non-histone chromosome protein HMG-I (Y) (25). This motif is typically 
a short repeat of glycine and arginine flanked by a proline at one or both ends. The 
central Arg-Gly-Arg of the AT-hook inserts into the minor groove of AT-rich DNA, 
where there are interactions between arginine and thymidine (26). Many of the proteins 
with AT-hook have been shown to have an effect on the architecture of chromatin at 
levels beyond the action of the basic histones and also play a role in transcription 
regulation (25).   
 Transmembrane domains are regions of a protein that are generally hydrophobic, 
so they prefer to be inserted into cell membranes such that parts of the protein on either 
side of the domain are on opposite sides of the membrane (27).  Integral membrane 
proteins have transmembrane domains that insert directly into lipid bilayers such as the 
plasma membrane (28).   
 Glycosylation is one of the most common posttranslational modifications of 
proteins and it plays a variety of important roles in many cellular events ranging from 
structural to signaling and recognition (29). Glycosylation types are classified according 
to the identity of the atom of the amino acid, which binds the carbohydrate chain, that is 




glycosylation sites according to bioinformatics analysis and this refers to the attachment 
of oligosaccharides to a nitrogen atom, usually the N4 of asparagine residues. N-
glycosylation often occurs on secreted or membrane bound proteins, mainly in eukaryotes 
and archaea (30). 
 Based on the fact that FAM171B has a putative AT-Hook DNA binding domain, 
one may hypothesize that FAM171B may function in the nucleus and perhaps bind DNA. 
Alternatively, transmembrane domains suggest that FAM171B may instead localize to 
cellular membranes such as ER, golgi or the plasma membrane. However, whether any of 
these domains found in FAM171B actually function as predicted remains to be 
empirically determined. Indeed, this study’s primary aim is to determine FAM171B’s 







 The overall objective of this project is to identify the intracellular localization of 
FAM171B in several different nervous system cell types- a human glioblastoma cell line 
(U138), a human neuroblastoma cell line (SH-SY5Y) and primary neurons harvested 
from mouse brain.  
 
Prediction 
 Based on the aforementioned bioinformatics data, FAM171B may function either 
in the nucleus or as a membrane bound protein. Thus, we predicted that FAM171B would 
localize to the nucleus or the plasma membrane (or both) of the cell. 
 
 To test this, we utilized both FAM171B-FLAG and FAM171B-GFP expression 
vectors (previously constructed in the lab) to express FAM171B fusion protein in several 
neuronal cell types. Transfected cells were fixed and analyzed using fluorescent confocal 
microscopy to determine the subcellular location of FAM171B fusion proteins. We also 
performed immunofluorescence on fixed U138 cells, SH-SY5Y cells and primary 
neurons to examine endogenously expressed FAM171B using commercially available 
antibodies. In addition, we performed co- immunofluorescence studies using an antibody 
against Neu N (a marker for neurons) to ensure that at least some of the cells harvested 
from mouse brains were indeed primary neurons. We also used organelle specific 




localization. Finally, we conducted live-cell imaging on SH-SY5Y cells transfected with 

























Materials and Methods 
 
2.1 Culturing U138 cells 
 
 U138 cells were grown in Eagle’s Minimum Essential Medium (EMEM) 
(supplemented with 10% fetal bovine serum). When cells were confluent (after 6-7 days) 
the cells were split into a new 25 ml flask. First old media was removed from the cell 
plate and 2 ml of phosphate buffered saline (1x PBS) was added to rinse and remove 
residual media. Next, 2 ml of PBS+EDTA was added and incubated for 2 minutes to 
detach cells from the plate. After 2-5 minutes in the incubator the cells detach from the 
surface and then 2-3 drops of cells were added to a new 25 ml flask containing 6 ml of 
EMEM media. This process was done weekly. 
 
2.2 Culturing primary neurons 
 
Mouse brains were purchased from Brain Bits LLC, and cultured according to 
their protocol as follows. 
 
Preparing cell dissociation solution 
 3 mL of hibernate solution (HE-Ca) was directly added into the 6 mg vial of 




bath for 10 min to dissolve. After 10 min, the vial was removed from the water bath and 
placed on ice to cool for 10 min. 
 
Cell Dispersal 
 Using the Pasteur pipette the brain tissue was removed with minimal hibernate 
(HEB) media and placed in the cell dissociation solution. The cell dissociation solution 
was sealed and then incubated in the 30 °C water bath for 10 minutes, gently swirling for 
every 5 minutes. Using the Pasteur pipet the tissue was removed with minimal cell 
dissociation solution and placed the tissue back into the vial containing HEB media. With 
the Pasteur pipette the tissue was drawn with the HEB media into the pipette and was 
dispensed the content into the vial immediately. This was repeated for ~1 min for 90% 
tissue dispersal. After this, the vial was not disturbed until undispersed pieces settle for 1 
min. Next the supernatant containing dispersed cells was transferred to a sterile 15 mL 
tube.  This was spin at 1100 rpm (200xG) for 1 min. The supernatant was discarded 
leaving ~ 50 µl of HEB media containing the pellet. The pellet of cells was dispersed by 
flicking the bottom of the tube with a finger and re-suspended in 1 ml of NbActiv1 
culture medium. After re-suspending, 32 µl of the cell dispersed solution was added on to 
each well containing Poly-D-Lysine coated coverslips. Coverslips for primary neurons 
were coated with Poly-D-Lysine solution to enhance the cell attachment. The amount cell 
dispersed solution was increased based on the need of the cell density reducing the 





2.3 Culturing SH-SY5Y cells 
 
 SH-SY5Y cells were growing in a media that was prepared using EMEM and F-
12 (1X) nutrient mixture (50:50). When the cells are confluent, cells were split into a new 
T-25 Flask. First, culture media was transferred to a centrifuge tube. The flask was then 
rinsed with 2 ml of PBS. Next, 2 ml PBS+EDTA was added and flask was incubated at 
37 °C for 3 minutes. Contents of the flask were then transferred to the respective 
centrifuge tube. The tube was then centrifuged for 3 minutes at 1000xg. Next the 
supernatant was discarded and the cell pellet was resuspended in 4 ml of fresh media. 
Then 1 ml of resuspended cells was added to a new flask containing 5 ml of fresh media.  
 
2.4 Coverslip Preparation for Primary Neurons 
 
Preparing coverslips with Poly-D-Lysine solution 
 Coverslips were added to each well in 6 well plates (10 plates) and sterilized 
overnight under the UV light. The following day 150 µL of Poly-D-Lysine solution 
(Brain Bits) was added onto the middle of each coverslip and incubated for 2-3 hours. 
After incubation, excess Poly-D-Lysine was removed and the coverslips were rinsed with 
tissue culture grade water (~1 ml per well). Next, the water was removed and coverslips 






2.5 Transfection with FAM171B-GFP 
 
 U138 cells were growing on coverslips in a 6 well plate (~5-6 drops of cells were 
added to each well). The following day, 5 µg of plasmid FAM171B-GFP (678 ng/µl) was 
added into 250 µL of opti-MEM media (for 6 wells = 30 µg /1500µL). Next, 10 µL of 
Lipofecatamine 2000, a transfection reagent that is used to increase the transfection 
efficiency of plasmid DNA, was diluted in 250 µL of opti-MEM (for 6 wells = 60 
µL/1500µL). The two dilutions were let to sit for 5 minutes and then combined and 
incubated for another 20 minutes. After 20 minutes 500 µL of the transfection material 
was dripped down gently into each well containing U138 cells. This was incubated for 4-
5 hours at 37 °C and media was changed into fresh EMEM. Next the transfected cells 
were fixed in either Methanol or Paraformaldehyde (4%).  
 
2.6 Transfection with FLAG-FAM171B  
 
 U138 cells were growing on coverslips in a 6 well plate (~5-6 drops of cells were 
added to each well). The following day, 5 µg of plasmid FLAG-FAM171B (341 µg/ml) 
was added into 250 µL of opti-MEM media (for 6 wells = 30 µg /1500µL). Next, 10 µL 
of Lipofecatamine 2000, a transfection reagent that is used to increase the transfection 
efficiency of plasmid DNA, was diluted in 250 µL of opti-MEM (for 6 wells = 60 
µL/1500µL). The two dilutions were let to sit for 5 minutes and then combined and 




was dripped down gently into each well containing U138 cells. This was incubated for 4-
5 hours and media was changed into fresh EMEM. Next, cells were fixed in methanol 
and immunofluorescence protocol was followed as mentioned below with primary 
antibody: Mouse anti FLAG (1:100) and secondary antibody Goat anti Mouse- Alexa: 
568 (Novus) (1:600). 
 
2.7 Cell Fixation 
 
Methanol Fixation 
 First the media was removed and coverslips were rinsed in 1x PBS (2 ml per 
well). Next, 2 ml of ice-cold methanol was added onto coverslips. Coverslips were fixed 
for 3 min. After fixing, the coverslips were removed from methanol and allowed to air-
dry. If the fixation was performed after transfection procedure, coverslips were mounted 




 Similar to above, old media was first removed and coverslips were washed gently 
with 1x PBS (2 ml per well) to remove old media and floating dead cells. Cells were then 
be fixed with 1 ml of 4% paraformaldehyde solution for 15 min. at room temperature. 
After fixing transfected coverslips, cells were washed 3 times with 1x PBS (2 ml per 




 When paraformaldehyde was used to fix the cells, additional steps were 
performed as follows to increase the cell permeability before performing the 
immunofluorescence procedure. After fixing coverslips with 4% paraformaldehyde for 15 
min. cells were rinsed with 1x PBS 3 times (2 minutes wait time at each wash). Next, 
cells were permeabilized with 0.2%- Triton –x100 in PBS for 3 minutes. In this step 
coverslips were treated with 50 µl of this solution. Then coverslips were rinsed with 1x 
PBS 3 times (2 minutes wait time at each wash) and once with 1x TBS. After these steps 
were done, coverslips were subjected to blocking with TBS/10% milk and other steps 
were followed as mentioned below for immunofluorescence procedure.  
 
Mounting coverslips onto slides after the fixation 
After fixing, coverslips were rehydrated by rinsing with 1x PBS twice (2ml per 
well). After this, coverslips were rinsed with water. One drop of Vectashield mounting 
medium (Vector laboratories) was added onto a microscope slide. Excess water was 
removed from the coverslips by wicking, and then coverslips were slowly dropped onto 
the drop of vectashield on the slide (cell side down). The four sides of the coverslip were 









2.8 Immunofluorescence  
 
 To perform IF experiments, fixed cells were rinsed with 2 ml of PBS (1x) three 
times for 2 minutes. Then the coverslips were rinsed with 2 ml of TBS (1x) once for 2 
minutes. After the rinsing steps, the coverslips were blocked in TBS/10% milk (50µl) for 
2 hours at the room temperature in a humidified chamber. Next, the cells were incubated 
with primary antibody Rabbit-FAM171B (Novus) (1:100) overnight at 4°C. Afterward 
the cells were washed with 2ml of TBS/Tween 6 times for 5 minutes. After the washing 
step, the cells were incubated with secondary antibody, Goat anti Rabbit – Alexa 488 
(1:500) at the room temperature for 2 hours. Then the cells were rinsed with 2 ml of 
TBS/T, 6 times for 5 minutes. The last step was to rinse the cells with deionized water 
and then coverslips were mounted with 5 µl of Vectashield Antifade with DAPI. The 
coverslips were then sealed using clear nail polish and the cells were observed using 
confocal microscopy. 
 
2.9 Confocal microscopy 
 
 Images were taken using the Zeiss LSM 880 confocal microscope. Per 
experimental coverslip, minimum of 10 cells were analyzed. For every image taken in 
this study, Plan-Apochromat 63x/1.4 NA oil objective lens was utilized. In Zen Blue 2.3 
software, “locate” option was selected to enable the specimen to be viewed through the 




1.5 mm thickness coverslips specialized for this microscope and for live cell imaging a 4-
well chambered coverglass was used. To set the microscope for fluorescence observation, 
blue/red/green emission channels were selected based on the staining we had on our cells. 
Once the region of interest was found and focused, “acquisition” option was selected to 
analyze the specimen in the computer using Zen blue 2.3 software.  Confocal-4 color 
parameter was selected each time for image acquisition. After scanning the image, “range 
indicator” was activated, in which the scanned image appears in false-color 
representation. Red pixel indicates the saturation (maximum intensity) and blue pixels 
indicates zero or minimum intensity. To achieve the optimal intensity, with minimal 
background signal, digital gain, digital offset and laser power parameters were adjusted. 
The “snap” tool was used to acquire single frame (multi-channel) images. To better 
evaluate the images, Z –stacking strategy was utilized. It is a digital image processing 
method, which combines several images captured at several focal distances. This process 
gives rise to composite image with a bigger depth of field than any of the individual 
images from which the composite image is created. In acquiring Z-stack images, two 
ends of the specimen were set using the focus knob and the interval between each stack 
was set to optimal setting. Orthogonal views of the images in x, y and z planes were 
studied to identify FAM171B localization inside the cell. To obtain the live cell imaging, 
time-series option was utilized. The number of cycles and the interval between each 






2.10 Co-localization with a Mitochondrial marker  
 
 Immunofluorescence protocol was followed as mentioned above. Primary 
antibody: Mouse anti Mitochondria (1:50) and secondary antibody: Goat anti Mouse: 
Alexa 568 (1:500) were used with the primary and secondary antibodies of FAM171B.  
 
2.11 Live cell  
 
 Live cell imaging was performed using confocal microscope on SH-SY5Y cells 
after transfecting with FAM171B-GFP.  First the cells were split in to a chambered 
coverglass, specifically designed for live cell imaging (4 wells).  The SH-SY5Y cell 
pellet after centrifuging was resuspended in 2 ml of the media (refer to the SH-SY5Y 
culture protocol above). Next 0.5 ml of resuspended pellet was added to each well in the 
chambered coverglass.  The following day, 1.25 µg of plasmid pEGFP-FAM171B (0.928 
µg/ml) + 2.5 µL of P3000 reagent were added into 62.5 µL of opti-MEM media (for 4 
wells = 5 µg+10 µL /250µL). Next, 2.5 µL of Lipofecatamine 3000, a transfection 
reagent that is used to increase the transfection efficiency of plasmid DNA, was diluted in 
62.5 µL of opti-MEM (for 4 wells = 10 µL/250µL). The two dilutions were then 
combined and incubated for another 15 minutes at room temperature. After 15 minutes 
125 µL of the transfection material was dripped down gently into each well containing 





2.12 Co-localization with early endosome marker in live cells 
 
 When performing live cell imaging with early endosome marker and FAM171B-
GFP, 2 µl of CellLight Early Endosome- RFP marker was dripped down to cell wells 30 
seconds prior to adding the transfection reagents. Images were taken in between cycles of 
20-300 with intervals ranging from 1.5 seconds to 2 seconds. Cells were maintained at 
5% CO2, 37°C conditions. For each well 5-8 respective images were obtained using the 









3.1 Immunofluorescence using two different antibodies suggests that FAM171B 
localizes to punctate vesicles in the cytoplasm of Primary neurons, SH-SY5Y 
Neuroblastoma cells and U138 Glioblastoma cells. 
 
 We performed immunofluorescent experiments using two commercially available 
primary polyclonal antibodies (Novus 93847) and (Novus 93846) to assay FAM171B’s 
intracellular localization in several different neuronal cell lines (Figures 1 and 2). The 
Novus 93847 Ab showed that FAM171B localizes predominantly to the cytoplasm of 
cells in discrete punctate dots reminiscent of small endomembrane system vesicles 
(Figure 1). Occasionally it appeared that FAM171B may be in/near the nucleus of certain 
cells (co-stained with DAPI); however, Z-stack images taken using the confocal 
microscope suggested that FAM171B predominantly localized to the cytoplasm (Figures 
3-5).  Interestingly, all three cell lines (glioblastoma, neuroblastoma and primary 
neurons) showed very similar staining patterns (Figure 1) suggesting that this is likely 
FAM171B’s intracellular distribution in many/most nervous system cell types. 
Importantly, we confirmed these results using a second primary antibody raised against a 
different epitope of FAM171B (Figure 2). Indeed, Novus 93846 primary Ab showed very 
similar staining patterns with punctate/vesicular type staining of FAM171B throughout 
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Figure 1: FAM171B displays a punctate cytoplasmic staining in primary neurons, 
SH-SY5Y cells and U138 cells (Immunofluorescence, Novus 93847 rabbit polyclonal 
Ab). Blue indicates DAPI nuclear stain and green indicates the expression of FAM171B. 













     DAPI           FAM171B      Merged   
 
 
Figure 2: FAM171B displays punctate cytoplasmic staining in primary neurons, SH-
SY5Y cells and U138 cells. (Immunofluorescence, Novus 93846 rabbit polyclonal 
Ab). Blue indicates DAPI nuclear stain and green indicates the expression of FAM171B. 














Figure 3: Orthogonal view of the merged image of U138 (Immunofluorescence, 
Novus 93846 rabbit polyclonal Ab) indicates FAM171B predominantly localizes to 
the cytoplasm of the cell. Blue indicates DAPI nuclear stain and green indicates the 






Figure 4: Orthogonal view of the merged image of SH-SH5Y (Immunofluorescence, 
Novus 93846 rabbit polyclonal Ab) indicates FAM171B predominantly localizes to 
the cytoplasm of the cell. Blue indicates DAPI nuclear stain and green indicates the 





Figure 5: Orthogonal view of the merged image of primary neuron 
(Immunofluorescence, Novus 93846 rabbit polyclonal Ab) indicates FAM171B 
predominantly localizes to the cytoplasm of the cell. Blue indicates DAPI nuclear stain 




3.2 FAM171B-GFP expression in fixed U138 cells 
 
 Exogenous expression of FAM171B was then studied by transfecting U138 cells 
with a FAM171B-GFP fusion protein plasmid (previously constructed in the lab). Similar 
to what we observed with immunofluorescence, FAM171B-GFP expression was 
predominantly localized to the cytoplasm of transfected cells (Figure 6). Also, 
FAM171B-GFP had a similar cytoplasmic vesicular staining pattern and intriguingly it 
could be seen more concentrated closer to the plasma membrane. These data suggest that 










       DAPI         FAM171B               Merged 
 
Figure 6.  FAM171B-GFP displays a punctate signaling pattern in U138 cells (fixed).  
Blue indicates DAPI nuclear stain and green indicates FAM171B (Methanol was used for 


















































Figure 7: Orthogonal view of transfected U138 cell with FAM171B-GFP (merged 
image) indicates FAM171B localizes predominantly to the cytoplasm of the cell. 




3.3 FAM171B-FLAG expression in fixed U138 cells  
 
  DAPI    FLAG    Merged 
 
Figure 8: FAM171B-FLAG localizes to the cytoplasm of U138 cells. Red signaling 
indicates the expression of FAM171B and DAPI in blue indicates the nucleus. Methanol 
was used for fixation.  
 
 To further examine the exogenous expression of FAM171B and its intracellular 
localization, we utilized a second fusion protein, FAM171B-FLAG (previously 
constructed in our lab) to transfect U138 cells. FAM171B-FLAG also localizes to the 
cytoplasm of the cell and displays a vesicular/punctate-staining pattern (Figure 8), similar 
to what we witnessed in transfection studies with GFP fusion protein and 
immunofluorescence data. This further validates the similarity between the endogenous 






Figure 9: Orthogonal view of the merged image of U138 cell transfected with 
FAM171B-FLAG shows FAM171B predominantly localizes to the cytoplasm of the 





 In order to analyze whether this punctate signaling pattern changes with different 
amounts of plasmid, U138 cells were subjected to transfection with varying amounts of 
FAM171B-GFP plasmid, ranging from 10 ng to 10 µg. It was observed that at each 
plasmid concentration, FAM171B’s punctate/ vesicular signaling pattern continued to be 
consistent, confirming that plasmid concentration does not affect the signaling pattern of 
the protein (Figure 10). At lower concentrations of the plasmid, the number of transfected 
cells was reduced and 5 µg of plasmid was used in our successive experiments. Moreover 
two fixing methods were tested: paraformaldehyde and methanol. We found no 
differences in expression pattern between the two fixing methods and methanol was used 
in most experiments (data not shown).  Figure 10 shows transfections with three lower 
concentrations of FAM171B-GFP plasmid: 10ng, 100ng, 500ng, and at each 
concentration, FAM171B shows the same signaling pattern.  
  A)       B)       C) 
 
Figure 10: FAM171B-GFP exhibits similar expression pattern at different plasmid 




500ng. Green signaling depicts FAM171B signaling and blue signaling depicts where the 
nucleus is.  Methanol was used for fixation. 
 
3.4 Co-immunofluorescence of FAM171B and NeuN in primary neurons  
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  FAM171B   Merged 
Figure 11: FAM171B is expressed in the cytoplasm of neurons. Red indicates the 
NeuN signaling, green indicates the FAM171B expression (Novus 93846 polyclonal 




 Primary neurons in our study were harvested from mouse brain cerebellum 
purchased from Brain Bits LLC. To confirm the cells we study are indeed neurons, 
NeuN, a neuronal biomarker that is used to identify neurons was utilized.  Harvested 
primary neurons were subjected to co-immunofluorescence using antibodies against 
FAM171B (Novus 93846) and against NeuN (Figure 11). Red signaling indicates the 
staining of NeuN, which signifies the presence of primary neurons. This confirmed that 
the cells we were analyzing were indeed neuronal cells.  
 
 3.5 Co-immunofluorescence of FAM171B and mitochondria in primary neurons  
 
 In attempt to identify the subcellular localization of the FAM171B in the cell, 
different organelle markers were utilized to analyze possible co-localization. Primary 
neurons were subjected to co- immunofluorescence with antibodies against mitochondria 
in the neurons and with antibodies against FAM171B (Figure 12). Based on the acquired 
data it was noticed that FAM171B does not co-localize with mitochondrial organelles, as 
little signal overlap was detected (Figure 13). This indicated that FAM171B protein 
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Figure 12: FAM171B does not co-localize to mitochondria in primary neurons. Red 
signaling indicates the mitochondria and green signaling indicates the FAM171B 






Figure 13: Orthogonal view of the merged image of primary neuron, subjected to 
co-immunofluorescence with antibody against FAM171B (Novus 93846) and 




3.6 Pseudopod-like protrusions.  
 
 
Figure 14: FAM171B localizes to pseudopod protrusions near the plasma 
membrane in cells. U138 cell was subjected to IF and green signaling indicates the 
expression of FAM171B (Novus 93847 polyclonal antibody).  
 
 We observed that FAM171B signals localizes to cellular regions near plasma 
membrane that resembles pseudopod-like cellular structures. Interestingly, this cellular 
characteristic was observed in both fixed and live cell imaging (SH-SY5Y cells). 
Enlarged cross sections of U138 cells depicted above (Figure 14) show pseudopod like 
plasma membrane protrusions and vesicular FAM171B signaling could be seen alongside 




were obtained (taking multiple images at different focal distances) and these membrane 
protrusions were noticed at certain stacks.  
  
3.7 Live- cell imaging 
 
 To gain more insight on FAM171B’s expression in real time in its cellular 
environment, we performed live cell imaging on SH-SY5Y cells. We first transfected the 
cells with FAM171B-GFP and live cell imaging showed vesicular green particles moving 
in the cytoplasm of the cell resembling the process of vesicular trafficking (Link 1). Also 
there were pseudopod like protrusions emanating from the edges of the plasma membrane 
of these live cells (Link 2) which was also observed in Z-stack images of the fixed 
transfected U138 cells and cells that were subjected to immunofluorescence. Interestingly 
it could be seen that these dynamic cellular structures in live cells were constantly 
extending and retracting from the cell membrane.  
 Next the live cells were co-stained with early endosome marker after transfecting 
the cells with FAM171B-GFP. It was observed that approximately one-half of the 
FAM171B-GFP signaling localizes to early endosome in live SH-SY5Y cells suggesting 
FAM171’s possible function in endocytic processes (Link 3).  Cell nuclei were stained in 
blue using the Hoechst DNA stain, and again FAM171B expression was typically not 
found in the nucleus. Figure 15 below shows a screen capture of live-cells after co-





 FAM171B       E. Endosome   Merged 
 
Figure 15: FAM171B co-localizes with early endosomes in live SH-SY5Y cells. Green 
signaling: expression of FAM171B and red: expression of early endosome in the cell. 
Blue signaling indicates the nucleus of the cell and yellow signaling indicates the co-
localization of FAM171B and early endosomes (red arrows).  
 
Link 1: 
SH-SY5Y Neuroblastoma cells : 33 hours post-transfection: This live-cell video shows 
the punctate vesicular signaling of FAM171B in SH-SY5Y cells, moving in the 
cytoplasm (60 seconds). 
Link 2: 
SH-SY5Y Neuroblastoma cells: 31 hours post-transfection: This video shows an enriched 
staining of FAM171B near the plasma membrane and highlights the dynamic cellular 






SH-SY5Y Neuroblastoma cells: Co-localization with early endosomes: 72 hours post-
transfection: This video shows co-localization of FAM171B with early endosomes. 
Yellow signaling specifies the overlap of FAM171B with early endosomes (4 seconds).  







 FAM171B is a novel polyQ protein with 14 glutamine repeats in its amino acid 
sequence.  There is minimal published data regarding this protein and its location and the 
function are yet to be determined. Based on characteristics it shares with other 
neurodegenerative diseases caused by abnormal expansions in the polyQ regions, 
FAM171B could also be linked to another molecularly uncharacterized 
neurodegenerative disease. Previous research conducted in our lab found that this novel 
protein is expressed widely throughout the developing and adult mouse brain through two 
different approaches, in situ hybridization and immunohistochemistry analysis. Moreover 
it was found that expression levels are more prominent in some brain regions compared 
to others.  
 The purpose of the current research was to further expand the knowledge of this 
protein by looking into the intracellular localization. Proteins are responsible for a 
multitude of diverse vital tasks in all living organisms. Given that a protein’s function 
and role are strongly related to its subcellular location, protein location prediction is an 
important research area (31). It can provide useful insights about their functions, 
particularly, one of the fundamental goals in cell biology and proteomics is to identify the 
functions of proteins in the context of compartments that organize them in the cellular 
environment (32). It can indicate how and in what kind of cellular environments the 




the in-depth study of protein-protein interaction (PPI). Also it can help our understanding 
of the intricate pathways that regulate biological processes at the cellular level and hence 
it is crucial for many studies in system biology (33). Furthermore it is very useful for 
identifying and prioritizing drug targets during the process of drug development (32). 
 To obtain intracellular localization data of FAM171B, three different cell lines 
were used in this study: human glioblastoma cells (U138), human neuroblastoma cells 
(SH-SY5Y) and mouse primary neurons. Furthermore, two distinct approaches were 
utilized- immunofluorescence (with two separate antibodies) and fusion protein 
expression using both FLAG and green fluorescent protein (GFP) tags. Cells were also 
fixed using two different approaches (methanol and paraformaldehyde). In addition, 
colocalization with subcellular markers (nucleus, mitochondria, and endosomes) was 
performed. Finally, time-lapse imaging of SH-SY5Y live cells expressing FAM171B-
GFP was performed to further understand the dynamic nature of FAM171B movement 
within cells. 
 Immunofluorescence (IF) was studied in all three cell lines and our data showed 
that FAM171B displayed a consistent punctate/vesicular type expression pattern (Figures 
1,2). This signaling predominantly localized to the cytoplasm of the cell and this 
characteristic was observed in every cell line and fixation method used. Z-stack images of 
the cells were taken to create 3D images and those images were used to confirm that 
FAM171B is expressed in the cytoplasm (Figures 3-5). 
 Next, cells were transfected with plasmids created in our lab to confirm whether 




Cells were first transfected with FAM171B-GFP, and we found that FAM171B-GFP 
signaling localizes to the cytoplasm of the cell, and displayed a punctate/vesicular type 
signaling in the cytoplasm similar to IF data for FAM171B (Figure 6). Different 
quantities of plasmid were used with varying amounts of Lipofectamine 2000 
(transfection reagent) to transfect the cells to analyze if the signaling pattern changes 
based on the plasmid/transfection reagent concentration (Figure 10). The signaling 
pattern continued to display the same cytoplasmic punctate/vesicular stain, although we 
observed that at lower plasmid concentrations only few cells were transfected and at high 
concentration more cells were transfected (Figure 10). 
 Next, cells were transfected with a different FAM171B fusion protein constructed 
in our lab. This fusion protein has a tag called FLAG, consisting of eight amino acids 
(AspTyrLysAspAspAspAspLys) (34) and immunofluorescence was performed with 
antibodies against FLAG peptide sequence. FLAG-FAM171B signaling, similar to the 
GFP transfection and IF data, was localized to the cytoplasm of cells further validating 
our data (Figure 8).  
 After analyzing the IF and transfection data it was noted that FAM171B is a 
cytoplasmic protein and next we tried to utilize organelle specific markers to find the 
subcellular location of the protein. First, primary neurons were stained with a 
mitochondrial marker and our data indicated that FAM171B and mitochondria do not co-
localize well as little signal overlap was observed (Figures 12,13). We are confident that 




cells derived from the mouse brain also stained for the neuronal marker NeuN (Figure 
11). 
The punctate/vesicular expression suggests that FAM171B could be a protein 
associated with vesicular transport. To further explore this possibility, we utilized an 
early endosomal marker in conjunction with FAM171B-GFP and found a strong 
colocalization between the two (Figure 15). Indeed, when subjected to live cell imaging 
these two vesicle compartments moved in tandem in the same direction (Figure 15, Link 
3). These results strongly suggest that FAM171B is at least occasionally present in 
endosomes. Thus, FAM171B may play a role within vesicular trafficking system 
(specifically endosomes) or it may itself be trafficked as cargo either in or out of the cell. 
Transport vesicles play a central role in the traffic of molecules between different 
membrane-enclosed compartments of the secretory pathway and endocytic pathway 
which is important for organelle biogenesis, constitutive and regulated secretion and 
endocytosis (35,36).  
 Efficient sorting of the material internalized by endocytosis is essential for key 
cellular functions and represents a major trafficking pathway in mammalian cells (37). 
Incoming material such as solutes, receptors and cargos, lipids and even pathogenic 
agents are routed to various destinations within mammalian cells at two major sorting 
stations: the early and late endosome (37). Sorting events initiated at early endosomes 
determine the subsequent fate of internalized proteins and lipids, destining them either for 
recycling to the plasma membrane, degradation in lysosomes or delivery to the trans-




the endocytic, biosynthetic and autophagic pathways and outgoing traffic to the 
lysosomes, the golgi complex or the plasma membrane (37). Our data suggest that 
FAM171B could be a protein functioning in cellular endocytosis since approximately 
half of our GFP-FAM171B signaling was co-localizing with early endosome markers in 
live-cell imaging and due to the punctate/ vesicular type expression in live and fixed 
cells. Moreover these vesicular structures were denser in the peripheral area of the cell 
where early endosomes usually reside in the cell.  
 Furthermore it was observed that these cells (fixed and live) show pseudopod-like 
protrusions around the edges of the cell membrane (Figure 14, Link 2). In fixed cells it 
was detected at different Z-stacks. In these protrusions FAM171B vesicles could be 
detected. These protrusions were prominent in live-cell imaging, and could be seen 
growing and retracting over the course of minutes (Link 2). The ability of cells to extend 
cell membranes is central to numerous biological processes, including cell migration, 
axon pathfinding, cadherin-mediated junction formation and phagocytosis (39). Moreover 
plasma membrane regions that form new protrusions could arise from the flow of 
membrane components from other regions of the cell, including vesicles such as 
endosomes (40).  
 Basquin et al (41), revealed a new mechanism that they call protrusion-based 
endocytosis, which is used to internalize receptors into small vesicles. In their work, they 
showed that interleukin-2 receptor (IL-2R) endocytosis requires its recruitment at the 
base of protrusions via its association with the WAVE complex (41). The WAVE 




complex, inducing actin polymerization and membrane protrusion (41). These findings 
suggest that the cellular protrusion we observed in our cells could be playing a role in 
endocytosis further supporting FAM171B’s possible function in the process.  
 One more possibility of these cellular protrusions observed in static and live cells 
is that this could be functioning in axon path finding or synapse formation 
(synaptogenesis). A common theme regarding the synaptogenesis is that growing axons 
explore their pathways and target regions by elaborating many dynamic, often transient 
protrusive filopodia and branchlets (42). Filopodia are long and slender cellular 
protrusions, which are one of the types of pseudopoda, have roles spanning the initiation 
and guidance of neuronal processes, axons and dendrites (43). This highly protrusive 
behavior of filopoda appears to be essential to the axon’s ability to pathfind and locate 
appropriate target cells (42). Extensions and retractions of cellular protrusions was a 
prominent feature in our live cell imaging of SH-SY5Y cells.  
 In order to further evaluate this position, future studies could include studying co-
localization of FAM171B with other organelle markers such as late endosomes. Also if 
this protein is functioning in endosome activity and if the expression of this protein is 
inhibited by gene knock out, complications in endocytosis process would be expected to 
be seen. Moreover pseudopod like protrusions might also be inhibited if the gene for 









 FAM171B is a novel polyglutamine protein with 14 glutamine repeats in its 
amino acid sequence. There is minimal publish data regarding this protein such that its 
function and its intracellular location have yet to be discovered. Based on the homology 
this protein shares with other polyQ neurodegenerative diseases, this could also be linked 
to another unknown polyQ disease. Previous research done in our lab found out that this 
protein is widely expressed throughout the mice brain using two different approaches: in-
situ hybridization and immunohistochemical identification. This current research was 
undertaken to figure out the intracellular location of this protein using 
immunofluorescence and transfection studies. Our data indicate that FAM171B 
predominantly localizes to the cytoplasm of the cell. This was consistent between every 
cell line we analyzed. Expression pattern displayed a punctate/vesicular signaling and 
these signaling was more pronounced closer to the plasma membrane of the cell. Live-
cell imaging data revealed that FAM171B-GFP localized to early endosomes. Moreover 
pseudopods like cellular cell membrane protrusions were observed in static and live cells. 
Taken together, these data suggest that FAM171B may play a role in cellular activities 
near the plasma membrane such as endocytosis and/or axon pathfinding. If FAM171B is 
linked to an unknown neurodegenerative disease, it could be contributing to the 
pathogenesis by disrupting the endosome function or by inhibiting the formation of 
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